| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Loss on the extinguishment of debt | - | 0 |
| Net loss | -3,581,863 | -2,104,052 |
| Depreciation | 0 | 0 |
| Change in the fair value of derivative conversion feature | 602,569 | 595,273 |
| Change in the fair value of obligation to issue shares | -2,095,299 | - |
| Foreign exchange gain | 71,084 | - |
| Loss on the extinguishment of debt | 0 | - |
| Other expense | 1,930,000 | 1,930,000 |
| Interest expense | 1,779,362 | 1,273,031 |
| Imputed interest expense | 187,242 | - |
| Loss on impairment of inventory included in cost of goods sold | 1,506,292 | 1,046,203 |
| Goods and services tax receivable | -1,079 | 4,497 |
| Accounts receivable | 580,559 | 101,199 |
| Inventory | 1,290,689 | 1,005,211 |
| Deferred revenue | 0 | 0 |
| Royalty payable | 289,810 | 55,599 |
| Accounts payable and accrued liabilities | 677,734 | 384,499 |
| Change in the fair value of obligation to issue shares | - | 1,926,944 |
| Accrued interest | 0 | 0 |
| Cash used in operating activities | -1,850,544 | -1,047,844 |
| Proceeds from issuance of share purchase warrants | 0 | 0 |
| Proceeds from notes payable | 0 | 0 |
| Proceeds from loans payable to related parties | 1,849,315 | 1,062,663 |
| Proceeds from convertible notes | 0 | 0 |
| Repayment of convertible notes | 0 | 0 |
| Cash provided by financing activities | 1,849,315 | 1,062,663 |
| Net change in cash | -1,229 | 14,819 |
| Cash and cash equivalents at beginning of period | 2,156 | - |
| Cash and cash equivalents at end of period | 927 | - |
CANNAPHARMARX, INC. (CPMD)
CANNAPHARMARX, INC. (CPMD)